Versie door Update bot(overleg | bijdragen) op 18 apr 2026 om 18:31 (Nieuwe pagina aangemaakt met '<!-- Hieronder wordt een transclude page aangeroepen --> {{Versions-2.16.840.1.113883.2.4.3.11.60.40.3.9.8(EN)|1|AdministrationAgreement-v3.1(2026-1EN)}} <!-- Tot hier de transclude page --> ==General information<!--hdGeneralInformation-->== Name<!--hdName-->: '''nl.zorg.AdministrationAgreement''' link=Toedieningsafspraak-v3.1(2026-1NL)<BR> Version<!--hdVersion-->: '''3.1''' <br> HCIM Status<!--hdStatus-->:Final<br> Release<!--hdPubli…')
An administration agreement is the pharmacist’s instruction for use or administration to the patient, the patient’s representative, or the administrator, by which the medication agreement is specified in concrete terms.
Purpose
The goal of the administration agreement is to provide insight into the concrete instructions for administration/use of medication.
Information Model
Type
Id
Concept
Card.
Definition
DefinitionCode
Reference
NL-CM:9.8.20132
AdministrationAgreement
Root concept of the AdministrationAgreement information model. This root concept contains all data elements of the AdministrationAgreement information model.
Identification of a medication treatment. A pharmaceutical treatment is defined as a treatment with a medicinal product. The PharmaceuticalTreatmentID is a technical identifier (worldwide and forever unique) that is required to record the relationship between a set of medication-related data elements. An identically defined PharmacotherapeuticTreatmentID has been added to all medication-related Health and Care Information Models (HCIMs): MedicationAgreement, MedicationAdministration2, AdministrationAgreement, MedicationUse2, MedicationDispense, and DispenseRequest.
One ore more dispense agreement that have been discontinued or modified and for which this agreement is a replacement. When recording a new medication agreement that is intended to discontinue or modify one ore more existing agreement, the dispense agreement changes accordingly. Here it is possible to explicitly indicate which previous dispense agreements the discontinuation relates to. This reference is used in combination with the corresponding discontinuation type and any reason for changing or discontinuing.
Reason for changing, discontinuing, or cancelling the administration agreement. This will often be the same reason as the reason for changing, discontinuing, or cancelling the medication agreement. Where applicable, it is possible to record a specific reason for changing, discontinuing, or cancelling the administration agreement.
160121000146101 Reason for change of drug administration instructions
Start date: This is the time at which the agreement was to take effect (or took effect or will take effect). This is the time at which the instructions for use in this agreement start. In the case of an agreement to discontinue use, this is the start date of the original administration agreement. The end date indicates from when the medication is to be discontinued.
Duration: The intended duration of use. E.g. 5 days or 8 weeks. It is not allowed to indicate the duration in months, because different months have a variable duration in days.
End date: The time at which the period of use ends (or ended or will end). In the case of an agreement to discontinue use, this is the time at which the medication is to be discontinued. To avoid confusion between 'to' and 'up until and including', the submission of time is always mandatory for the end date.
With medication for an indefinite period only a start date is indicated.
Vanaf 2 mei gedurende 4 weken zo nodig bij pijn 500 mg (=1 st), max. 4x per dag
oraal
1
4 weken
1 stuk
max. 4x/dag
Bij pijn
Gedurende 5 dagen 1x/dag (8u) 40 mg (=1 st)
iv
40 mg (=1 st)
1x per dag om 8.00 uur
Vanaf 19-9-2014 tot 18-12-2014 1x per dag om 18uur 2500ie(=0,2ml)
subcutaan
2500 IE (=0,2 ml)
1x per dag om 18.00 uur
Van 1-8-2013 tot 30-8-2013 volgens afbouwschema. Per 30-8-2013 onderbreken.
oraal
1
Instructions
The rules about linking an existing PharmaceuticalTreatmentID or to issue a new PharmaceuticalTreatmentID have been determined by the Medication Process information standard established by Nictiz.
Assigning authorities
The identifying numbers are issued by the following authorities
Technical specifications in HL7v3 CDA and HL7 FHIR
To exchange information based on health and care information models, additional, more technical specifications are required.
Not every environment can handle the same technical specifications. For this reason, there are several types of technical specifications:
HL7® version 3 CDA compatible specifications, available through the Nictiz ART-DECOR® environment
HL7® FHIR® compatible specifications, available through the Nictiz environment on the Simplifier FHIR
AdministrationAgreement
PharmaceuticalTreatmentID
or as spreadsheet 